Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, China.
Department of Cardiology, Changhai Hospital, Navy Medical University, China.
Oxid Med Cell Longev. 2023 Feb 4;2023:3271057. doi: 10.1155/2023/3271057. eCollection 2023.
The pharmacological mechanism of the traditional Chinese medicine formula-Jijiu Huiyang decoction (JJHYD), which contains several herbal medicines for the treatment of chronic heart failure (CHF), is yet unknown. . The main active components of JJHYD were analyzed by ultrahigh-performance liquid chromatography-mass spectrometry (UHPLC-MS/MS). The target genes of JJHYD and CHF were retrieved through multiple databases, a drug-ingredient-target-disease network was created, and KEGG enrichment and GO analyses were carried out. The binding ability of paeonol and Glycogen Synthase Kinase-3 alpha (GSK3A) was confirmed by molecular docking. CHF animal model and cell model were constructed. The effects of paeonol on cardiac dysfunction, myocardial hypertrophy, cardiac lipid accumulation, and myocardial apoptosis were detected by echocardiography, histopathology, and flow cytometry, respectively. The effects of paeonol on the expression of myocardial hypertrophy index, GSK3A, and genes or proteins related to the PPAR pathway were determined by qRT-PCR or western blot.
UHPLC-MS/MS analysis combined with database verification showed a total of 227 chemical components in JJHYD, among which paeonol was the one with heart-protective roles and had the highest content. Paeonol alleviated isoproterenol-induced cardiac lipid accumulation, cardiac hypertrophy, and myocardial dysfunction and inhibited the activation of the PPAR pathway, while overexpression of GSK3A reversed these effects of paeonol. However, the reversal effects of GSK3A overexpression could be offset by siPPAR.
As the main active substance of JJHYD, paeonol participates in the protection of CHF by targeting the GSK3A/PPAR signaling pathway to reduce lipid toxicity.
用于治疗慢性心力衰竭(CHF)的中药方剂 - 九回阳汤(JJHYD)包含几种草药,但其药理学机制尚不清楚。通过超高效液相色谱-质谱联用(UHPLC-MS/MS)分析 JJHYD 的主要活性成分。通过多个数据库检索 JJHYD 和 CHF 的靶基因,构建药物-成分-靶标-疾病网络,并进行 KEGG 富集和 GO 分析。通过分子对接验证丹皮酚与糖原合酶激酶-3α(GSK3A)的结合能力。构建 CHF 动物模型和细胞模型。通过超声心动图、组织病理学和流式细胞术分别检测丹皮酚对心脏功能障碍、心肌肥大、心脏脂质积累和心肌细胞凋亡的影响。通过 qRT-PCR 或 Western blot 测定丹皮酚对心肌肥大指标、GSK3A 以及与 PPAR 通路相关的基因或蛋白表达的影响。
UHPLC-MS/MS 分析结合数据库验证表明,JJHYD 中共有 227 种化学成分,其中丹皮酚具有心脏保护作用,含量最高。丹皮酚减轻异丙肾上腺素诱导的心脏脂质积累、心肌肥大和心肌功能障碍,并抑制 PPAR 通路的激活,而过表达 GSK3A 可逆转丹皮酚的这些作用。然而,GSK3A 过表达的逆转作用可以被 siPPAR 抵消。
作为 JJHYD 的主要活性物质,丹皮酚通过靶向 GSK3A/PPAR 信号通路减少脂质毒性,参与 CHF 的保护。